Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms: HELP
Articles by Maike Ahrens
Based on 3 articles published since 2010
(Why 3 articles?)

Between 2010 and 2020, Maike Ahrens wrote the following 3 articles about Pancreatic Neoplasms.
+ Citations + Abstracts
1 Article Annexin A10 optimally differentiates between intrahepatic cholangiocarcinoma and hepatic metastases of pancreatic ductal adenocarcinoma: a comparative study of immunohistochemical markers and panels. 2017

Kälsch, Julia / Padden, Juliet / Bertram, Stefanie / Pott, Leona L / Reis, Henning / Westerwick, Daniela / Schaefer, Christoph M / Sowa, Jan-P / Möllmann, Dorothe / Fingas, Christian / Dechȇne, Alexander / Sitek, Barbara / Eisenacher, Martin / Canbay, Ali / Ahrens, Maike / Baba, Hideo A. ·Institute of Pathology, University Hospital of Essen, University of Duisburg-Essen, Hufelandstr. 55, 45147, Essen, Germany. · Department of Gastroenterology and Hepatology, University Hospital of Essen, University of Duisburg-Essen, Hufelandstr. 55, 45147, Essen, Germany. · Medizinisches Proteom-Center, Ruhr-Universität Bochum, Universitätsstr 150, 44780, Bochum, Germany. · Department of General, Visceral and Transplantation Surgery, University Hospital of Essen, University of Duisburg-Essen, Hufelandstr. 55, 45147, Essen, Germany. · Institute of Pathology, University Hospital of Essen, University of Duisburg-Essen, Hufelandstr. 55, 45147, Essen, Germany. hideo.baba@uk-essen.de. ·Virchows Arch · Pubmed #28357490.

ABSTRACT: Discriminating intrahepatic cholangiocarcinoma (ICC) from hepatic metastases of pancreatic ductal adenocarcinoma (mPDAC) can be challenging. While pathologists might depend on clinical information regarding a primary tumor, their diagnosis will lead the patient either to potentially curative surgery (for ICC) or to palliation (for mPDAC). Beyond the validation of recently published potential biomarkers for PDAC (primary or metastatic) in a large cohort, we assessed diagnostic performance of the most promising candidates in the challenging task of discriminating metastatic PDAC (mPDAC) from ICC. In a training set of 87 ICC and 88 pPDAC, our previously identified biomarkers Annexin A1 (ANXA1), ANXA10, and ANXA13 were tested and compared with 11 published biomarkers or panels (MUCIN 1, Agrin, S100P, MUC5 AC, Laminin, VHL, CK 17, N-Cadherin, ELAC2, PODXL and HSPG2). Biomarkers with best results were further tested in an independent series of biopsies of 27 ICC and 36 mPDAC. Highest AUC values (between 0.72 and 0.84) for the discrimination between ICC and pPDAC were found in the training set for Annexin A1, Annexin A10, MUC5 AC, CK17, and N-Cadherin. These markers were further tested on an independent series of liver biopsies containing ICC or mPDAC. Diagnostic characteristics were evaluated for individual markers as well as for 3× panels. ANXA 10 showed the highest diagnostic potential of all single markers, correctly classifying 75% of mPDAC and 85% of ICC. Our results suggest that ANXA10 may be useful to differentiate between ICC and mPDAC, when only a tissue specimen is available.

2 Article Immunohistochemical Markers Distinguishing Cholangiocellular Carcinoma (CCC) from Pancreatic Ductal Adenocarcinoma (PDAC) Discovered by Proteomic Analysis of Microdissected Cells. 2016

Padden, Juliet / Ahrens, Maike / Kälsch, Julia / Bertram, Stefanie / Megger, Dominik A / Bracht, Thilo / Eisenacher, Martin / Kocabayoglu, Peri / Meyer, Helmut E / Sipos, Bence / Baba, Hideo A / Sitek, Barbara. ·From the ‡Medizinisches Proteom-Center, Ruhr-Universität Bochum, Germany; juliet.padden@rub.de. · From the ‡Medizinisches Proteom-Center, Ruhr-Universität Bochum, Germany; · §Institut für Pathologie, Universitätsklinikum Essen, Universität-Duisburg-Essen, Germany; · ¶Klinik für Allgemeinchirurgie, Viszeral- und Transplantationschirurgie, Universitätsklinikum Essen, Universität-Duisburg-Essen, Germany; · ‖Institut für Pathologie und Neuropathologie, Abteilung Allgemeine Pathologie, Universitätsklinikum Tübingen, Germany. ·Mol Cell Proteomics · Pubmed #26644413.

ABSTRACT: Cholangiocellular carcinoma (CCC) and pancreatic ductal adenocarcinoma (PDAC) are two highly aggressive cancer types that arise from epithelial cells of the pancreatobiliary system. Owing to their histological and morphological similarity, differential diagnosis between CCC and metastasis of PDAC located in the liver frequently proves an unsolvable issue for pathologists. The detection of biomarkers with high specificity and sensitivity for the differentiation of these tumor types would therefore be a valuable tool. Here, we address this problem by comparing microdissected CCC and PDAC tumor cells from nine and eleven cancer patients, respectively, in a label-free proteomics approach. The novel biomarker candidates were subsequently verified by immunohistochemical staining of 73 CCC, 78 primary, and 18 metastatic PDAC tissue sections. In the proteome analysis, we found 180 proteins with a significantly differential expression between CCC and PDAC cells (p value < 0.05, absolute fold change > 2). Nine candidate proteins were chosen for an immunohistochemical verification out of which three showed very promising results. These were the annexins ANXA1, ANXA10, and ANXA13. For the correct classification of PDAC, ANXA1 showed a sensitivity of 84% and a specificity of 85% and ANXA10 a sensitivity of 90% at a specificity of 66%. ANXA13 was higher abundant in CCC. It presented a sensitivity of 84% at a specificity of 55%. In metastatic PDAC tissue ANXA1 and ANXA10 showed similar staining behavior as in the primary PDAC tumors (13/18 and 17/18 positive, respectively). ANXA13, however, presented positive staining in eight out of eighteen secondary PDAC tumors and was therefore not suitable for the differentiation of these from CCC. We conclude that ANXA1 and ANXA10 are promising biomarker candidates with high diagnostic values for the differential diagnosis of intrahepatic CCC and metastatic liver tumors deriving from PDAC.

3 Article Circulating U2 small nuclear RNA fragments as a novel diagnostic biomarker for pancreatic and colorectal adenocarcinoma. 2013

Baraniskin, Alexander / Nöpel-Dünnebacke, Stefanie / Ahrens, Maike / Jensen, Steffen Grann / Zöllner, Hannah / Maghnouj, Abdelouahid / Wos, Alexandra / Mayerle, Julia / Munding, Johanna / Kost, Dennis / Reinacher-Schick, Anke / Liffers, Sven / Schroers, Roland / Chromik, Ansgar M / Meyer, Helmut E / Uhl, Waldemar / Klein-Scory, Susanne / Weiss, Frank U / Stephan, Christian / Schwarte-Waldhoff, Irmgard / Lerch, Markus M / Tannapfel, Andrea / Schmiegel, Wolff / Andersen, Claus Lindbjerg / Hahn, Stephan A. ·Department of Molecular Gastrointestinal Oncology, Ruhr-University Bochum, Bochum, Germany. ·Int J Cancer · Pubmed #22907602.

ABSTRACT: Improved non-invasive strategies for early cancer detection are urgently needed to reduce morbidity and mortality. Non-coding RNAs, such as microRNAs and small nucleolar RNAs, have been proposed as biomarkers for non-invasive cancer diagnosis. Analyzing serum derived from nude mice implanted with primary human pancreatic ductal adenocarcinoma (PDAC), we identified 15 diagnostic microRNA candidates. Of those miR-1246 was selected based on its high abundance in serum of tumor carrying mice. Subsequently, we noted a cross reactivity of the established miR-1246 assays with RNA fragments derived from U2 small nuclear RNA (RNU2-1). Importantly, we found that the assay signal discriminating tumor from controls was derived from U2 small nuclear RNA (snRNA) fragments (RNU2-1f) and not from miR-1246. In addition, we observed a remarkable stability of RNU2-1f in serum and provide experimental evidence that hsa-miR-1246 is likely a pseudo microRNA. In a next step, RNU2-1f was measured by qRT-PCR and normalized to cel-54 in 191 serum/plasma samples from PDAC and colorectal carcinoma (CRC) patients. In comparison to 129 controls, we were able to classify samples as cancerous with a sensitivity and specificity of 97.7% [95% CI = (87.7, 99.9)] and 90.6% [95% CI = (80.7, 96.5)], respectively [area under the ROC curve 0.972]. Of note, patients with CRC were detected with our assay as early as UICC Stage II with a sensitivity of 81%. In conclusion, this is the first report showing that fragments of U2 snRNA are highly stable in serum and plasma and may serve as novel diagnostic biomarker for PDAC and CRC for future prospective screening studies.